

Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready to Start	Date of First Patient Recruited	Non-Confirmation Status	Duration between Date site selected and First Patient (days)	Benchmark Met	A - Permissions delayed/ denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
16/WS/0068	199202	Quantitative Fibronectin to help Decision-making in women with Symptoms of Preterm Labour - QUIDS	19/05/2016	03/10/2016	13/07/2016	27/06/2016	10/08/2016	31/10/2016	02/11/2016		30	Yes											SIV delayed by sponsor. Final protocol presented by sponsor at SIV (03/10/2016) which necessitated additional communication to resolve agreement to continue.	
16/LO/1822	212944	A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFREF) - Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA)	11/05/2017	05/10/2016	07/12/2016					Site declined to participate		Site Not Confirmed											Site declined 06/01/2017 - PI no longer able to act as PI. No other consultant able to take on the role of PI for the duration of the study.	
17/EM/0075	222172	Evaluating the tolerance, compliance and acceptability of a nutritionally complete, high energy, high protein, enteral feed in adults ? a pilot study	01/02/2017	27/03/2017	27/03/2017	24/04/2017	02/05/2017	08/05/2017	17/05/2017		51	Yes								Y			Final complete costing template not received until 24/04/2017 from sponsor.	Both
16/HRA/5525	210175	MindSHINE 3: A definitive randomised controlled trial investigating two online wellbeing interventions to reduce NHS staff stress	17/01/2017	06/04/2017	23/01/2017	06/04/2017	08/05/2017	15/05/2017	06/06/2017		61	Yes												
17/YH/0071	223653	A MULTICENTER OPEN-LABEL EXTENSION (OLE) STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF BEMPEDOIC ACID (ETC-1002) 180 MG	03/04/2017	11/05/2017	19/07/2017	29/06/2017	04/07/2017	30/08/2017	01/09/2017		113	No											1. HRA approval for the study was not received until 19/07/17 (initial HRA assessment letter dated 22/02/17) - cause of delay not known by site. 2. Patients entering this extension study can only do so when they have fully completed the sister study. Our first eligible patient completing the sister study was seen and recruited to this study within the protocol required timelines. 3. Sponsor could not provide an earlier date for the Site Initiation Visit.	Sponsor

Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready to Start	Date of First Patient Recruited	Non-Confirmation Status	Duration between Date site selected and First Patient (days)	Benchmark Met	A - Permissions delayed/ denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
16/NW/0517	188554	A phase III study to determine the role of ixazomib as an Augmented Conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT Consolidation and maintenance strategy in patients with Relapsed multiple myeloma.	29/09/2016	05/04/2017	27/10/2016	08/08/2017	18/08/2017					No					Y						Delay due to time taken for study review and consultation by local clinicians. Local information pack of documents was provided to site prior to site having a confirmed PI.	NHS Provider
17/SC/0142	215503	Evaluating the clinical and cost-effectiveness of permissive hypotension in critically ill patients aged 65 years or over with vasodilatory hypotension	03/03/2017	11/05/2017	24/04/2017	18/08/2017	29/08/2017	01/09/2017	02/09/2017		114	No					Y						1. The sponsor required GCP training of staff at site prior to release of sponsor signed contract - staff availability issues to undertake GCP training at the NHS Provider caused a delay. 2. Sponsor and NHS Provider could not find an early mutually agreeable date for the Site Initiation Visit which also created a delay.	Both
13/SC/0645	143871	Prognostic indicators of severe disEAsE in women with late preterm pre-eClampsia IO guide deCision maKing on timing of delivery	21/03/2016	26/04/2017	15/06/2016	26/04/2017	17/05/2017	29/06/2017	12/07/2017		77	No						Y					Strict patient eligibility criteria apply to this study and hence low numbers of women are seen in our maternity services who are eligible for the study.	Neither